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1. General information 
Synthetic procedures 
Starting materials, reagents and solvents were purchased from Sigma–Aldrich, Acros, Fluka, Fischer, 
TCI and were used as received. Solvents for the reactions were of quality puriss., p.a.. Anhydrous 
solvents were purified by passage through solvent purification columns (MBraun SPS-800). For 
aqueous solutions, deionized water was used. Thin Layer Chromatography analyses were performed 
on commercial Kieselgel 60, F254 silica gel plates with fluorescence-indicator UV254 (Merck, TLC silica 
gel 60 F254). For detection of components, UV light at λ = 254 nm or λ = 365 nm was used. 
Alternatively, oxidative staining using aqueous basic potassium permanganate solution (KMnO4) or 
aqueous acidic cerium phosphomolybdic acid solution (Seebach’s stain) was used. Drying of solutions 
was performed with MgSO4 and volatiles were removed with a rotary evaporator. Flash column 
chromatography was performed with Silicagel, pore size 60 Å, 40-63 µm particle size. 
 
Analytical procedures  
Nuclear Magnetic Resonance spectra were measured with an Agilent Technologies 400-MR (400/54 
Premium Shielded) spectrometer (400 MHz). All spectra were measured at room temperature (22–24 
°C). The multiplicities of the signals are denoted by s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet), br (broad signal).All 13C-NMR spectra are 1H-broadband decoupled. High-resolution 
mass spectrometric measurements were performed using a Thermo scientific LTQ OrbitrapXL 
spectrometer with ESI ionization. The ions are given in m/z-units. Melting points were recorded using 
a Stuart analogue capillary melting point SMP11 apparatus. For spectroscopic measurements, 
solutions in Uvasol® grade solvents were measured in a 10 mm quartz cuvette. UV/Vis absorption 
spectra were recorded on an Agilent 8453 UV/Vis spectrophotometer with diode array detection. 
Temperature-control was exerted through a Peltier based temperature controlled cuvette holder 
(QuantumNorthwest). Fluorescence measurements were performed on a BioTek Synergy H1 
microplate reader. ICP-OES analysis was performed on a Perkin Elmer Optima 7000 DV spectrometer. 
NMRD profiles were recorded on a Stelar 0.25 T FFC relaxometer SMARtracer. 
 
Irradiation sources 
Irradiation experiments were performed with a λ = 400 nm LED system (3 x 330 mW, λmax = 401 nm, 




2. Synthetic procedures 
 
 
2: 2-Isocyano-N-(prop-2-yn-1-yl)acetamide. Prepared by a modification of a literature procedure.1 A 
mixture of methyl isocyanoacetate (7.82 mmol, 711 µL) and propargylamine (15.61 mmol, 1.00 mL) 
was stirred at room temperature overnight. The formed solid was filtered off and washed with 
diethyl ether to provide compound 2 as light brown powder (759 mg, 78%). Rf = 0.63 
(pentane/AcOEt, 1:1, v/v); Mp. 109°C; 1H NMR (400 MHz, DMSO-d6):  3.15 (t, 4J = 2.4 Hz, 1H, CCH), 
3.88 (dd, 3J = 5.6 Hz, 4J = 2.4 Hz, 2H, CH2NH), 4.35 (s, 2H, CH2NC), 8.61 (br s, 1H, NH). 1H NMR 
spectrum is in agreement with published data.2 
 
3: 1-(4,5-Dimethoxy-2-nitrophenyl)-2-oxo-2-((2-oxo-2-(prop-2-yn-1-ylamino)ethyl) amino)-ethyl 4-
bromobutanoate. A solution of compound 2 (1.62 mmol, 200 mg), 6-nitroveratraldehyde (1.34 
mmol, 285 mg) and 4-bromobutyric acid (1.62 mmol, 270 mg) in chloroform (2.7 mL) was stirred at 
room temperature for 48 h. The volatiles were evaporated and the product was purified by flash 
column chromatography (pentane/AcOEt, 8:2 to 2:8, v/v) to give a white powder (373 mg, 56%). Rf = 
0.18 (pentane/AcOEt, 1:1, v/v); Mp. 142-143°C; 1H NMR (400 MHz, DMSO-d6):  2.03-2.12 (m, 2H, 
CH2CH2Br), 2.51-2.66 (m, 2H, CH2CH2CH2Br), 3.09 (t, 4J = 2.4 Hz, 1H, CCH), 3.48-3.63 (m, 2H, CH2Br), 
3.74 (d, 3J = 6.0 Hz, 2H, CH2NH), 3.82-3.85 (m, 2H, CH2CC), 3.87 (s, 3H, CH3O), 3.90 (s, 3H, CH3O), 6.60 
(s, 1H, CHO), 7.14 (s, 1H, ArH), 7.64 (s, 1H, ArH), 8.38 (t, 3J = 5.2 Hz, 1H, NH), 8.60 (t, 3J = 6.0 Hz, 1H, 
NH). 13C NMR (100 MHz, DMSO-d6):  28.1, 28.3, 32.3, 34.3, 42.1, 56.6, 56.8, 70.8, 73.6, 81.3, 108.7, 
111.9, 124.7, 141.8, 149.0, 153.2, 167.7, 168.6, 171.5. HRMS (ESI+) calc. for [M+H]+ (C19H23N3O8Br): 





4: 1-(Dodecan-2-yloxy)-3-(dodecyloxy)propan-2-ol. NaH (60% in mineral oil, 8.58 mmol, 206 mg) was 
added to dodecan-1-ol (18.0 mmol, 3.35 g) at 100°C. After stirring for 30 min, epichlorohydrin (4.2 
mmol, 0.39 g) was added dropwise and the mixture was stirred at 100°C overnight. H2O was added to 
quench the reaction, followed by DCM (50 mL). The aqueous phase was extracted with DCM, the 
collected organic phases were washed with brine and dried over MgSO4. Evaporation of volatiles and 
purification with flash column chromatography (pentane/AcOEt, 95:5, v/v) gave the product as a pale 
yellow solid (572 mg, 32%). Rf = 0.69 (pentane/AcOEt, 95:5, v/v); Mp. 30-32 °C; 1H NMR (400 MHz, 
CDCl3):  0.88 (t, 6H, CH3), 1.26-1.29 (m, 36H, CH3(CH2)9), 1.57 (m, 4H, CH2CH2O), 2.50 (d, 1H, OH), 
3.41-3.51 (m, 8H, (CH2OCH2)2CHOH), 3.92-3.96 (m, 1H, CHOH); 13C NMR (100 MHz, CDCl3):  14.1, 
22.7, 26.1, 29.3, 29.5, 29.6, 29.6, 29.7, 31.9, 69.5, 71.7, 71.8. 1H NMR spectrum is in agreement with 
published data.3 
 
S1: 1-(Dodecan-2-yloxy)-3-(dodecyloxy)propan-2-yl methanesulfonate. A solution of 
methanesulfonyl chloride (1.46 mmol, 167 mg) in DCM (1 mL) was slowly added to a solution of 
compound 4 (1.17 mmol, 500 mg) and triethylamine (1.46 mmol, 148 mg) in DCM (3 mL) at room 
temperature. The mixture was stirred for 2 h. AcOEt was added and the organic phase was washed 
with H2O and brine and dried (MgSO4). Evaporation of volatiles gave the product as a pale yellow 
solid (484 mg, 82%). Mp. 57°C. (lit. 58-59 °C).4 1H NMR (400 MHz, CDCl3):  0.88 (t, 6H, CH2CH3), 1.24-
1.32 (m, 36H CH3(CH2)9), 1.54-1.57 (m, 4H, CH2CH2O), 3.08 (s, 3H, SO2CH3), 3.41-3.51 (m, 4H, 
CH2CHOHCH2), 3.60-3.67 (m, 4H, CH2CH2O), 4.81 (q, 1H, CHOH). 1H NMR spectrum is in agreement 





5: 1-(2-Azido-3-(dodecan-2-yloxy)propoxy)dodecane. Compound S1 (0.79 mmol, 400 mg) and NaN3 
(6.30 mmol, 410 mg) were dissolved in DMF (3 mL) and the reaction mixture was stirred at 100°C 
overnight. AcOEt was added and the organic phase was washed with water and brine and dried 
(MgSO4). Evaporation of the volatiles gave the product as a yellow oil (294 mg, 82%). Rf = 0.53 
(AcOEt); 1H NMR (400 MHz, CDCl3):  0.88 (t, 6H, CH3), 1.26-1.30 (m, 36H, CH3(CH2)9), 1.54-1.60 (m, 
4H, CH2CH2O), 3.43-3.57 (m, 8H, CH2OCH2CHAzideCH2OCH2), 3.65-3.71 (q, 1H, CHAzide). 1H NMR 
spectrum is in agreement with published data.4 
 
6: 2-((2-(((1-(1,3-Bis(dodecyloxy)propan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)amino)-2-
oxoethyl)amino)-1-(4,5-dimethoxy-2-nitrophenyl)-2-oxoethyl 4-bromobutanoate. The compound 
was prepared by a modification of a literature procedure for a different target.5 To a solution of 
compounds 3 (0.12 mmol, 61 mg), and 5 (0.15 mmol, 66 mg) were added of DIPEA (5.5 µmol, 0.72 
mg) and acetic acid (5.5 µmol, 0.33 mg) in DCM (220 µL) and copper iodide (3 µmol, 0.6 mg).  The 
reaction mixture was stirred at room temperature overnight. The product was purified by flash 
column chromatography (pentane/AcOEt 1:9 v/v to pure AcOEt) to obtain the product as a yellow oil 
(67.7 mg, 58%). Rf = 0.80 (AcOEt); 1H NMR (400 MHz, CDCl3):  0.88 (t, 3J = 6.0 Hz, 6H, (CH2)11CH3), 
1.26-1.28 (m, 40H, CH3(CH2)9), 1.53 (m, 4H, (CH2)9CH2CH2O), 2.19 (q, 3J = 7.0 Hz 2H, CH2CH2Br), 2.60-
2.73 (m, 2H, CH2CH2CH2Br), 3.39-3.54 (m, 5H, CH2Br, (CH2)10CH2O), 3.81 (d, 3J = 8.0 Hz, 4H, CH2CH-
TriazoleCH2), 3.96 (s, 3H, OCH3), 3.89 (dd, 2J = 16.0 Hz, 3J = 6.0 Hz 2H, HNCOCH2NH), 4.01 (s, 3H, 
OCH3), 4.06 (dd, 2J = 16.0 Hz, 3J = 6.0 Hz, 2H, HNCOCH2NH) 4.51 (m, 2H, TriazoleCH2NHCO), 4.85 (m, 
1H, CHTriazole), 6.74 (s, 1H, ArCHO), 7.13 (t, 3J = 6.0 Hz, 1H, NH), 7.20 (s, 1H, ArH), 7.38 (t, 3J = 6.0 Hz , 
1H, NH), 7.60 (s, 1H, ArH), 7.70 (s, 1H, ArH); 13C NMR (100 MHz, CDCl3):  14.2, 22.8, 26.2, 27.7, 29.5, 
29.6, 29.6, 29.7, 29.8, 29.8, 29.8, 30.4, 32.0, 32.3, 32.6, 35.1, 43.1, 56.6, 56.8, 60.9, 69.3, 71.1, 71.8, 
108.1, 111.1, 114.1, 122.5, 124.6, 124.9, 140.8, 149.2, 153.8, 167.7, 168.2, 171.7. HRMS (ESI+) calc. 




7: 4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-ium bromide. The 
compound was prepared according to a literature procedure.6 A suspension of cyclen (5.81 mmol, 
1.00 g) and sodium acetate (19.1 mmol, 1.57 g) in N,N-dimethylacetamide (DMA, 12 mL) was stirred 
at -20°C. A solution of tert-butyl bromoacetate (19.2 mmol, 2.83 mL) in DMA (4 mL) was added 
dropwise over 15 minutes at -20 °C. The reaction mixture was stirred at room temperature for 24 h, 
after which it was poured into water (60 mL), resulting in a clear solution. Solid KHCO3 (30.0 mmol, 
3.00 g) was added portion-wise and a precipitate was formed. The precipitate was collected by 
filtration and dissolved in DCM (5 mL) and the solution was washed with water (20 mL), dried over 
MgSO4, filtered and concentrated to about 4-5 mL. Diethyl ether (50 mL) was added and compound 7 
precipitated as a white solid (1.64 g, 48%). Rf = 0.63 (DCM/MeOH, 9:1, v/v). Mp. 179-181 °C. 1H NMR 
(500 MHz, CDCl3) δ 1.45 (s, 9H), 1.46 (s, 18H), 2.87 (m, 4H), 2.93 (m, 8H), 3.10 (m, 4H), 3.29 (s, 2H), 




1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate. A solution of compound 6 (0.114 mmol, 109 
mg), compounds 7 (0.1 mmol, 50 mg,) and triethylamine (0.24 mmol, 34 µL) in acetonitrile (3 mL) 
was stirred at 60°C overnight. The volatiles were evaporated and the product was purified by flash 
column chromatography (DCM/Methanol 98:2 – 90:10, v/v) to give a yellow oil (35 mg, 22%). Rf = 




1H NMR (400 MHz, CDCl3):  0.88 (t, 6H, 1, 1’), 1.25 (m, 36H, 2-10, 2’-10’ ), 1.44-1.47 (m, 27H, 29), 
1.50-1.53 (m, 4H, 11, 11’), 1.83-3.18 (m, 28H, 23-28), 3.41 (m, 4H, 12, 12’), 3.80-3.83 (m, 4H, 13, 13’), 
3.93 (s, 3H, 21/22), 3.99 (s, 3H, 21/22), 4.05-4.10 (m, 2H, 17), 4.52-4.53 (m, 2H, 16), 4.83-4.84 9M, 
1H, 14), 6.82 (s, 1H, 18), 7.29 (s, 1H, 19/20), 7.51 (m, 1H, 30/31), 7.56 (s, 1H. 15), 7.81 (s, 1H, 19/20), 
8.46 (m, 1H, 30/31); 13C NMR (100 MHz, CDCl3):  14.1, 22.7, 26.0, 27.9, 28.0, 28.0, 28.2, 29.4, 29.4, 
29.5, 29.5, 29.6, 29.7, 31.9, 35.3, 43.2, 53.2, 53.4, 55.7, 56.4, 57.1, 60.6, 69.4, 70.6, 71.3, 71.7, 82.6, 
83.0, 83.0, 108.0, 111.6, 122.5, 125.1, 141.2, 144.5, 148.9, 153.5, 168.1, 169.0, 172.3, 172.3. HRMS 




tetraazacyclododecane-1,4,7-triyl)triacetic acid. A solution of compound S2 (0.020 mmol, 25 mg) in 
trifluoroacetic acid (1.4 mL) and tri-iso-propylsilane (1.4 mL) was stirred at room temperature for 5 h. 
The volatiles were evaporated in vacuo and the residue was triturated with diethyl ether to give 




1H NMR (400 MHz, MeOD):  0.9 (t, 6H, 1, 1’), 1.28 (m, 42 H, 2-11, 2’-11’, 23), 1.5 (m, 4 H, 24-25), 
3.05-3.7 (m, 22H, 26-28), 3.21 (m, 4H, 12, 12’), 3.82 (m, 4H, 13, 13’), 3.88-3.99 (m, 2H, 17), 3.93 (s, 
3H, 22/21), 3.96 (s, 3H, 22/21), 4.48 (s, 2H, 16), 4.9 (m, 1H, 14), 6.81 (s, 1H, 18), 7.25 (s, 1H, 19/20), 
7.69 (s, 1H, 19/20), 7.91 (s, 1H, 15). 13C NMR (100 MHz, MeOD):  14.5, 23.8, 27.2, 30.5 (m), 30.8 (m), 
31.6, 33.1, 35.7, 43.6, 57.0, 57.3, 62.5, 70.6, 72.5, 109.5, 113.1, 116.8 (TFA), 119.7 (TFA), 124.0, 
125.5, 142.9, 145.7, 150.8, 154.9, 162.8 (TFA), 163.2 (TFA), 170.5, 171.1, 173.0.  HRMS (ESI+) calc. for 
[M+H]+ (C60H102N10O16): 1219.7556, found: 1219.7548. 
3. Preparation of liposomes 
The liposomes were prepared by mixing equimolar amounts of compound 1 with DOPC in 
chloroform. After evaporation of the organic solvent, TBS buffer (0.9 mL, 50 mM Tris, 150 mM NaCl, 
pH 7.5) was added to the dry lipid film to yield a concentration of 2.78 mM for both components. Five 
cycles of freezing, thawing and ultrasound sonication afforded the final liposomes. A solution of 
gadolinium trichloride in TBS buffer (2.5 mM GdCl3, 0.1 mL) was added to the liposomes and 
incubated for 2 hours during gentle stirring. Afterwards, the liposomes were purified from free 
gadolinium salts via dialysis (benzoylated dialysis tubing, MWCO: 2000, Sigma Aldrich). 
4. Cryo-TEM and EDX analysis 
Cryo-TEM was performed on a Tecnai T20 electron microscope (FEI) operated at 200 keV using a 
Gatan model 626 cryo-stage. Samples were vitrified with a vitrobot (FEI) on quantifoil 3.5/1 grids. 
Images were recorded on a slow-scan CCD camera under low-dose conditions. EDX analysis was done 
on the same microscope using a X-max 80T SDD detector (Oxford instruments). The ratio of 
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phosphorus to gadolinium signal was analyzed in two selected areas and determined to be 1: 1.76 
(Gd/P). 
 
Fig. S1 (A) cryoTEM image of dialyzed liposomes, containing 50% DOPC and 50% compound 1, with 1 
equivalent of GdCl3 added. (B) EDX spectrum of an area of liposome aggregation after addition of 2 
equivalents of GdCl3 and after dialysis. (C) EDX spectrum of the background of the same sample as in 
B. The absence of gadolinium signal in C indicates the selective accumulation in the liposomes 
through the successful Gd(III)-complex formation. 
5. NMRD measurements 
The liposomes were prepared as described above. The relaxation rates were determined over a 
frequency range of 0.01 – 10 MHz at 37 ⁰C with 20 data points collected. The samples were irradiated 
in the NMRD vessel with λ = 400 nm for 60 min and NMRD profiles were recorded at the indicated 





Fig. S2 (A) NMRD profiles of three independently prepared samples of liposomes containing Gd-1 
(sample 1-3). (B) NMRD profiles of liposomes containing Gd-1 after preparation, after storage for one 
and four weeks.Spectrophotometric analysis 
The absorbance was analyzed on a UV/Vis spectrophotometer. The liposomal formulation was 
irradiated as described above and the samples diluted with DMSO for analysis of the UV-Vis 
absorbance. 
 
Fig. S3 (A) UV-Vis absorption spectra of liposomes containing Gd-1 before irradiation and after 
irradiation with λ = 400 nm for the indicated time points. (B) Visible change of the sample color upon 
irradiation 
6. Determination of relaxation rates at 4.7 T 
The relaxation rate of the liposomal formulation (prepared as described above) was determined on a 
Varian MercuryPlus spectrometer (4.7 T) at 37 ⁰C using an inverse recovery experiment. The sample 
was irradiated in the NMR tube with λ = 400 nm light for 60 min and the relaxation rates were 




Fig. S4 Relaxation rate at 4.7 T in the dark and after irradiation for the indicated times 
7. Determination of free Gd3+ concentration 
The concentration of free Gd3+ was quantified by determination of the ratio of absorbance intensity 
at λ = 573 nm and λ = 433 nm of a Gd3+-xylenol orange complex7 in ammonium acetate buffer (100 
mM, pH 5.8, 0.60 mM Xylenol Orange) using a microplate reader. The liposome sample was prepared 
as described above and diluted 1:20 with ammonium acetate buffer before analysis. The 
concentration of free Gd3+ before irradiation was determined as 0.029 mM. After irradiation for 60 
min with λ = 400 nm the free Gd3+ concentration was determined as 0.033 mM. 
 
Fig. S5 (A) Calibration curve showing the ratio of absorbance intensity at λ = 573 nm and λ = 433 nm 
for increasing Gd3+ concentration in the presence of xylenol orange (0.60 mM).  (B) Concentration of 
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free Gd3+ before and after irradiation with λ = 400 nm for 1 h and total gadolinium concentration 
(determined by ICP OES). 
8. Cargo release from liposomes 
The liposomes were prepared by adaptation of the method described above. A solution of calcein 
(0.1 M calcein, 0.1 M Tris buffer, pH 7.5) was used for hydration of the dry lipid film. The 
concentration of DOPC and compound 1 was 7 mM. The liposomes were purified from free calcein by 
size exclusion chromatography on a HiTrap desalting Sephadex G25 column using TBS buffer (0.1 M 
Tris, 0.15 M NaCl, pH 7.5) as elution buffer. The fluorescence (λexc = 490 nm, λem = 520 nm), indicating 
the amount of free calcein was analyzed on a microplate reader. At first the sample was kept in the 
dark for 60 minutes in order to assess the light-independent leakage of calcein. Subsequently, the 
sample was irradiated for 70 minutes with λ = 400 nm and the increase in fluorescence was checked 
every 10 minutes. At the end of the experiment, Triton X 100 (1% v/v) was added to determine the 
maximum calcein concentration. Liposomes consisting of only DOPC were prepared in the same way 
and analyzed as a control. Due to photobleaching of the fluorescence of the released calcein, it was 
not possible to determine the exact fraction of cargo release.  
  
Fig. S6 Fluorescence intensity (λexc = 490 nm, λem = 520 nm) of calcein-loaded liposomes containing 
compound 1 in the dark, upon irradiation with λ = 400 nm and after addition of Triton X 100.  
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9. Dynamic Light Scattering 
The size distribution of the liposomes was analyzed by Dynamic Light Scattering (DLS) using the 
Dynapro Nanostar apparatus, and the results were analyzed with Dynamics software, version 7. 
Before the analysis, the samples were diluted and centrifuged for 1 min at 10000 g to remove 
potential aggregates. As the irradiation progresses, the average size of the liposomes shifts towards 
smaller objects with a broader size distribution.  
 
Fig. S7 Size of liposomes containing Gd-1 in the dark and after irradiation for 60 min.   
10. In vitro analysis of liposome cytotoxicity 
Primary colonic epithelium cells were obtained from Tebu-Bio (The Netherlands, 2–96115). Cells 
were cultured in RPMI-1640 (Lonza, Swiss), supplemented with 10% fetal calf serum (FCS, Thermo 
Scientific Waltham, MA) ) at 37°C in a humidified 5% CO2 atmosphere.  
HUVEC cells were obtained from the UMCG Endothelial Cell Facility and were isolated and cultured 
by the method previously described.8  
Monocytes: PBMCs were subjected to magnetic-activated cell sorting (MACS) with anti-CD14-beads 
and MS columns (Miltenyi Biotec). Macrophages: monocytes (1 × 106/mL) were treated with 50 
ng/mL M-CSF for 6 d, yielding M0 macrophages. M0 macrophages were subsequently stimulated 
with 50 ng/mL LPS and 20 ng/mL IFNγ to generate M1 macrophages.9 
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To test liposome induced cytotoxicity HUVEC,normal epithelial cells or M1 macrophages were seeded 
in 48 wells plate at density of 2,0x104 cells per well. The next day cells were incubated for 48 hours 
(M1 macrophages 24 hours) with either medium or 10 µL liposomes solution which was irradiated 
with λ = 400 nm for the indicated time points. Treatment with high dose (70 µM) taxol (Merck) was 
added as a positive control for apoptosis measurement. After incubation cells were harvested and 
stained with Annexin V-FITC (Immunotools, Germany) and propidium Iodide (Merck) according to 
manufacturer’s protocol and analyzed by flow cytometry (Guava, Merck). 
 
Fig. S8 Percentage of Annexin V/PI positive cells (analyzed by flow cytometry) after addition of 





11. NMR spectra of new compounds 
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